217 related articles for article (PubMed ID: 36856148)
1. Randomized controlled trial of nalfurafine for refractory pruritus in hemodialysis patients.
Zhang P; Xiang S; Liu B; Wang X; Yang X; Ye C; Wang Z; Li Y; Zhou L; Wang C; Li H; Huang J; Peng A; Wang X; Wang D; Xiao J; Chen W; Cheng H; Mao N; Wang J; Yang L; Chen J
Ren Fail; 2023 Dec; 45(1):2175590. PubMed ID: 36856148
[No Abstract] [Full Text] [Related]
2. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study.
Kumagai H; Ebata T; Takamori K; Muramatsu T; Nakamoto H; Suzuki H
Nephrol Dial Transplant; 2010 Apr; 25(4):1251-7. PubMed ID: 19926718
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: A randomized, double-blind trial.
Kumada H; Miyakawa H; Muramatsu T; Ando N; Oh T; Takamori K; Nakamoto H
Hepatol Res; 2017 Sep; 47(10):972-982. PubMed ID: 27753159
[TBL] [Abstract][Full Text] [Related]
4. Clinical Profiles of Nalfurafine Hydrochloride for the Treatment of Pruritus Patients.
Miyamoto Y; Oh T; Aihara E; Ando A
Handb Exp Pharmacol; 2022; 271():455-472. PubMed ID: 33201326
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of a novel ĸ-agonist for managing intractable pruritus in dialysis patients.
Kumagai H; Ebata T; Takamori K; Miyasato K; Muramatsu T; Nakamoto H; Kurihara M; Yanagita T; Suzuki H
Am J Nephrol; 2012; 36(2):175-83. PubMed ID: 22868684
[TBL] [Abstract][Full Text] [Related]
6. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies.
Wikström B; Gellert R; Ladefoged SD; Danda Y; Akai M; Ide K; Ogasawara M; Kawashima Y; Ueno K; Mori A; Ueno Y
J Am Soc Nephrol; 2005 Dec; 16(12):3742-7. PubMed ID: 16251241
[TBL] [Abstract][Full Text] [Related]
7. Interventions for itch in people with advanced chronic kidney disease.
Hercz D; Jiang SH; Webster AC
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD011393. PubMed ID: 33283264
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Difelikefalin in Japanese Patients With Moderate to Severe Pruritus Receiving Hemodialysis: A Randomized Clinical Trial.
Narita I; Tsubakihara Y; Uchiyama T; Okamura S; Oya N; Takahashi N; Gejyo F;
JAMA Netw Open; 2022 May; 5(5):e2210339. PubMed ID: 35511180
[TBL] [Abstract][Full Text] [Related]
9. Anti-pruritic effect of nemolizumab in hemodialysis patients with uremic pruritus: a phase II, randomized, double-blind, placebo-controlled clinical study.
Kinugasa E; Igawa K; Shimada H; Kondo M; Funakoshi S; Imada N; Itami N; Fukazawa N; Takubo R; Kawata Y; Murota H
Clin Exp Nephrol; 2021 Aug; 25(8):875-884. PubMed ID: 33754202
[TBL] [Abstract][Full Text] [Related]
10. Nalfurafine hydrochloride to treat pruritus: a review.
Inui S
Clin Cosmet Investig Dermatol; 2015; 8():249-55. PubMed ID: 26005355
[TBL] [Abstract][Full Text] [Related]
11. Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study.
Yagi M; Tanaka A; Namisaki T; Takahashi A; Abe M; Honda A; Matsuzaki Y; Ohira H; Yoshiji H; Takikawa H;
J Gastroenterol; 2018 Oct; 53(10):1151-1158. PubMed ID: 29663077
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and Severity of Itching in Patients with End-Stage Renal Disease: Treatment with Nalfurafine Hydrochloride.
Nakamoto H; Kobayashi T; Noguchi T; Kusano T; Ashitani K; Imaeda H; Maezono M
Blood Purif; 2019; 47 Suppl 2():45-49. PubMed ID: 30943482
[TBL] [Abstract][Full Text] [Related]
13. Post-marketing surveillance study of the safety and efficacy of nalfurafine hydrochloride (Remitch
Kozono H; Yoshitani H; Nakano R
Int J Nephrol Renovasc Dis; 2018; 11():9-24. PubMed ID: 29391822
[TBL] [Abstract][Full Text] [Related]
14. Nalfurafine hydrochloride: a new drug for the treatment of uremic pruritus in hemodialysis patients.
Nakao K; Mochizuki H
Drugs Today (Barc); 2009 May; 45(5):323-9. PubMed ID: 19584962
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: Patient-reported outcome based analyses.
Kamimura K; Yokoo T; Kamimura H; Sakamaki A; Abe S; Tsuchiya A; Takamura M; Kawai H; Yamagiwa S; Terai S
PLoS One; 2017; 12(6):e0178991. PubMed ID: 28604788
[TBL] [Abstract][Full Text] [Related]
16. Shorter pruritus period and milder disease stage are associated with response to nalfurafine hydrochloride in patients with chronic liver disease.
Kawano T; Atsukawa M; Tsubota A; Shimada N; Toyoda H; Takaguchi K; Tani J; Morishita A; Hiraoka A; Mikami S; Ishikawa T; Okubo H; Watanabe T; Okubo T; Arai T; Hayama K; Itokawa N; Kondo C; Iwakiri K
Sci Rep; 2022 May; 12(1):7311. PubMed ID: 35508514
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety profiling of zolpidem and acupressure in CKD associated pruritus: An interventional study.
Rehman IU; Ahmed R; Rahman AU; Wu DBC; Munib S; Shah Y; Khan NA; Rehman AU; Lee LH; Chan KG; Khan TM
Medicine (Baltimore); 2021 May; 100(21):e25995. PubMed ID: 34032717
[TBL] [Abstract][Full Text] [Related]
18. A randomized controlled study of 6% gabapentin topical formulation for chronic kidney disease-associated pruritus.
Aquino TMO; Luchangco KAC; Sanchez EV; Verallo-Rowell VM
Int J Dermatol; 2020 Aug; 59(8):955-961. PubMed ID: 32459016
[TBL] [Abstract][Full Text] [Related]
19. Post-Marketing Surveillance Study of the Safety and Efficacy of Nalfurafine (Capsules 2.5 μg, Oral Dispersing Tablets 2.5 μg) in 1186 Patients with Chronic Liver Disease and Intractable Pruritus.
Yoshitani H; Ito J; Kozono H
Hepat Med; 2022; 14():37-66. PubMed ID: 35530746
[TBL] [Abstract][Full Text] [Related]
20. Pruritus in Hemodialysis Patients: Longitudinal Associations With Clinical and Patient-Reported Outcomes.
Sukul N; Zhao J; Pisoni RL; Walpen S; Schaufler T; Asgari E; Guebre-Egziabher F; Zho L; Abdulrahman Al-Ghonaim M; Nitta K; Robinson BM; Karaboyas A
Am J Kidney Dis; 2023 Dec; 82(6):666-676. PubMed ID: 37777951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
